Technical Analysis for CRVS - Corvus Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 1.96 | 16.67% | 0.28 |
CRVS closed up 16.67 percent on Wednesday, May 8, 2024, on 2.64 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Death Cross | Bearish | 16.67% | |
| Fell Below 200 DMA | Bearish | 16.67% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 9 hours ago |
| Rose Above Previous Day's High | about 13 hours ago |
| 5x Volume Pace | about 14 hours ago |
| 2x Volume Pace | about 14 hours ago |
| 1.5x Volume Pace | about 14 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/06/2024
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Cancer Cell Immune Checkpoint Adenosine Oncology Therapies Cd73
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Cancer Cell Immune Checkpoint Adenosine Oncology Therapies Cd73
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.19 |
| 52 Week Low | 1.05 |
| Average Volume | 240,506 |
| 200-Day Moving Average | 1.79 |
| 50-Day Moving Average | 1.78 |
| 20-Day Moving Average | 1.58 |
| 10-Day Moving Average | 1.69 |
| Average True Range | 0.20 |
| RSI (14) | 61.83 |
| ADX | 30.11 |
| +DI | 22.15 |
| -DI | 22.25 |
| Chandelier Exit (Long, 3 ATRs) | 1.51 |
| Chandelier Exit (Short, 3 ATRs) | 1.89 |
| Upper Bollinger Bands | 1.92 |
| Lower Bollinger Band | 1.23 |
| Percent B (%b) | 1.05 |
| BandWidth | 43.69 |
| MACD Line | 0.03 |
| MACD Signal Line | -0.04 |
| MACD Histogram | 0.0626 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.22 | ||||
| Resistance 3 (R3) | 2.20 | 2.10 | 2.17 | ||
| Resistance 2 (R2) | 2.10 | 2.04 | 2.11 | 2.16 | |
| Resistance 1 (R1) | 2.03 | 1.99 | 2.07 | 2.05 | 2.14 |
| Pivot Point | 1.93 | 1.93 | 1.95 | 1.94 | 1.93 |
| Support 1 (S1) | 1.86 | 1.87 | 1.90 | 1.88 | 1.78 |
| Support 2 (S2) | 1.76 | 1.82 | 1.77 | 1.76 | |
| Support 3 (S3) | 1.69 | 1.76 | 1.75 | ||
| Support 4 (S4) | 1.71 |
